Metraipolis › archive › dc_0fa212029dde
Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small… — Europe PMC PMID:41243674
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41243674
- DOI
- 10.1111/1759-7714.70192
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T20:33:33.389Z
- SHA-256 of the archived text
5d3e4c89321d9ad5a2af762da1e0da0e359e284bb5a5f5406c1e83a3cd4e3799- Stable URL of this page
https://metraipolis.com/documento/dc_0fa212029dde
How to cite
Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small… — Europe PMC PMID:41243674 — Europe PMC (en), https://europepmc.org/article/MED/41243674 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0fa212029dde (Metraipolis archive dc_0fa212029dde, sha256 5d3e4c89321d9ad5a2af762da1e0da0e359e284bb5a5f5406c1e83a3cd4e3799)
BibTeX
@misc{dc0fa212029dde,
title = {Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small… — Europe PMC PMID:41243674},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41243674},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0fa212029dde; sha256 5d3e4c89321d9ad5a2af762da1e0da0e359e284bb5a5f5406c1e83a3cd4e3799},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41243674. Agents can read the archived copy with the MCP tool read_document.